MimiVax

About:

MimiVax is a developer of immunotherapeutic vaccines and targeted therapies used to control tumor growth and recurrence.

Website: http://mimivax.com/

Twitter/X: mimivaxllc

Top Investors: Sontag Family Trust, Brain Tumor Investment Fund, MEDA Angels, Varia Ventures

Description:

MimiVax is a privately-held, clinical-stage biotechnology company that focuses on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. Its vaccines use survivin-targeting technology to target a cell-survival protein present in most cancers that enable healthcare providers to cure their patients. The company was founded in 2012 and is headquartered in Buffalo, New York.

Total Funding Amount:

$16.6M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Buffalo, New York, United States

Founded Date:

2012-01-01

Contact Email:

Mciesielski(AT)mimivax.com

Founders:

Michael Ciesielski, Robert Fenstermaker, Scott E. Friedman

Number of Employees:

1-10

Last Funding Date:

2024-01-09

IPO Status:

Private

Industries:

© 2025 bioDAO.ai